CIK 0001549595 · Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 270838048
- Phone
- (415) 660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-04-30 | van Houte Hans Chief Financial Officer | Option exercise | +2,886 | 36,610 | ||
| 2025-04-30 | van Houte Hans Chief Financial Officer | Option exercise | +2,000 | 38,610 | ||
| 2025-04-30 | van Houte Hans Chief Financial Officer | Option exercise | +3,750 | 42,360 | ||
| 2025-04-30 | van Houte Hans Chief Financial Officer | Sale | −2,438 | $11.50 | $28K | 39,922 |
| 2025-04-30 | van Houte Hans Chief Financial Officer | Option exercise · Restricted Stock Units | −2,886 | 8,659 | ||
| 2025-04-30 | van Houte Hans Chief Financial Officer | Option exercise · Restricted Stock Units | −2,000 | 8,000 | ||
| 2025-04-30 | van Houte Hans Chief Financial Officer | Option exercise · Restricted Stock Units | −3,750 | 30,000 | ||
| 2025-03-11 | Baynes Roy D. Director | Grant or award · Director Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2025-03-03 | van Houte Hans Chief Financial Officer | Sale 10b5-1 | −5,125 | $14.40 | $74K | 34,424 |
| 2025-03-03 | van Houte Hans Chief Financial Officer | Sale 10b5-1 | −700 | $15.13 | $11K | 33,724 |
| 2025-02-11 | SANDS ARTHUR T President, CEO | Grant or award · Employee Stock Option (right to buy) | +450,000 | 450,000 | ||
| 2025-02-11 | van Houte Hans Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2025-02-11 | van Houte Hans Chief Financial Officer | Grant or award · Restricted Stock Units | +34,300 | 34,300 | ||
| 2025-02-11 | Ring Christine Chief Legal Officer | Grant or award · Employee Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2025-02-11 | Ring Christine Chief Legal Officer | Grant or award · Restricted Stock Units | +34,300 | 34,300 | ||
| 2025-02-11 | Hansen Gwenn Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2025-02-11 | Hansen Gwenn Chief Scientific Officer | Grant or award · Restricted Stock Units | +34,300 | 34,300 | ||
| 2025-01-31 | Ring Christine Chief Legal Officer | Option exercise 10b5-1 | +223 | $1.86 | $415 | 32,761 |
| 2025-01-31 | Ring Christine Chief Legal Officer | Option exercise 10b5-1 | +5,537 | $1.86 | $10K | 38,298 |
| 2025-01-31 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −5,660 | $19.94 | $113K | 32,638 |
Page 14 of 20 · 381 trades